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A B S T R A C T
Objective: To evaluate the efﬁcacy of an immunostimulant (bacterial lysate) Broncho-Vaxom in the
management of children with recurrent acute tonsillitis.
Methods: A 5-year retrospective cohort study of 177 children presenting with a diagnosis of recurrent
acute tonsillitis. Patients’ demographics and laboratory studies at presentation were retrieved. For
patients given Broncho-Vaxom, we deﬁned response as a decrease in the frequency of acute tonsillitis
episodes after 3 months of therapy (partial: by 50% and total: by >50%). Patients showing response to
Broncho-Vaxom were further followed until study-end or need for tonsillectomy.
Results: Themedian age of patients was 4.5 years (range: 1–15 years) with 63.8% beingmales. 131 (74%)
patients received Broncho-Vaxom as initial therapy, and 99 (75.6%) showed response (51.2% total and
24.4% partial response). A normal ESR level was the only predictor of total compared with no response
(OR: 3.53, 95% CI: 1.03–12.07); while both normal ESR (OR: 7.15-times, 95% CI: 1.18–43.39) and normal
CRP (OR: 12.66, 95% CI: 1.43–111.86) levels were independent predictors of total over partial response.
None of the patients showing total response required tonsillectomy on long-term follow up while in
those with partial response 34.4% required subsequent tonsillectomy (median follow-up: 9 months).
Conclusions: A considerable proportion of children receiving Broncho-Vaxom for recurrent acute
tonsillitis show a decrease in the frequency of episodes in the short term, and very few patients
eventually require tonsillectomy on long-term follow up.
 2013 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Recurrent acute tonsillitis during childhood can result in
considerable morbidity and school absenteeism [1]. Decades of
experience using tonsillectomy for recurrent acute tonsillitis in
children have led to consensus that it is effective. However, recent
systematic reviews indicate that the level of evidence regarding
the ability of tonsillectomy to reduce the number of episodes of
sore throat is very low (modest size effect), except in children with
severe symptoms, and the decision to undergo tonsillectomy
should be clearly weighed against the potential harms including
intraoperative and postoperativemorbidity [2,3]. Whilst removing
the tonsils will always prevent ‘tonsillitis’, the impact of the
procedure on ‘sore throats’ is much less predictable [2,3].
Moreover, very few studies evaluated the effect of antibiotic* Corresponding author at: Department of Otolaryngology Head and Neck
Surgery, American University of Beirut Medical Center, P.O. Box 11-0236/A52,
Beirut 1107 2020, Lebanon. Tel.: +961 1 374444x5475, 5470, 5830;
fax: +961 1 370793.
E-mail address: mb36@aub.edu.lb (M.A. Bitar).
0165-5876/$ – see front matter  2013 Elsevier Ireland Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.ijporl.2013.01.009therapy on recurrence rates [4]. Thus, the search for alternative
interventions is ongoing.
Bacterial immunomodulators that contain killed bacteria, their
lysate or components of bacterial cells were proved to increase
efﬁciency of the immune system response, via both a speciﬁc as
well as a non-speciﬁc effect on the cellular and humoral
mechanisms [5]. Since the 1970s, when the concept of the
bacteria-derived immunomodulators appeared, various products
were developed and accepted mostly for the prevention of
recurrent respiratory tract infections. The OM-85 BV (Broncho-
Vaxom; OM Pharma, Geneva, Switzerland) preparation contains
lysates of eight bacterial pathogens (in equal parts) of the most
often encountered microorganisms in respiratory tract infections
[6]. As a bacterial immunostimulator, Broncho-Vaxom was shown
to affect both innate immunity inﬂuencing macrophages, neu-
trophils activity and proinﬂammatory cytokines production, as
well as acquired immune responses regulated by lymphocytes and
synthesis of immunoglobulins [7]. Results from a recent meta-
analysis showed that children treated with Broncho-Vaxom
experience signiﬁcantly and consistently fewer cases of recurrent
respiratory tract infections compared with controls (26.2% risk
difference) [6]. In this study, we aimed to evaluate the efﬁcacy of
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acute tonsillitis in speciﬁc, and determine predictors of response to
therapy.
2. Methods
Thiswas a retrospective observational cohort study of children
presenting to the Pediatric Otolaryngology Clinic at the American
University of Beirut Medical Center, Beirut, Lebanon between
January 1 2006 andDecember 31 2010. Inclusion criteriawere age
between 6months and 18 years and a diagnosis of recurrent acute
tonsillitis (more than three distinct episodes in the past 12months
[2]) on presentation to our clinic during the study period.
Exclusion criteria were immune deﬁciency, obstructive tonsils
necessitating tonsillectomy, and the use of immune modulators
other than the study drug. Patients are seen at our clinic at least 10
days after the last acute episode. Highly recurrent acute tonsillitis
was deﬁned as seven ormore episodes of acute tonsillitis in 1 year,
ﬁve episodes per year for two consecutive years, or three episodes
per year for three consecutive years [8]. Retrieved data at ﬁrst
presentation included age, sex, history of recurrent acute
tonsillitis, and results of laboratory studies (not taken during
acute illness): total hemoglobin level, white blood cell (WBC)
count, erythrocyte sedimentation rate (ESR), c-reactive protein
(CRP) level, urinalysis, antistrepolysin O (ASO) titer, and throat
cultures. The treatment modality used was also recorded
(Broncho-Vaxom, tonsillectomy, and antibiotics). For patients
receiving Broncho-Vaxom, response to therapy was evaluated 3
months from the start of treatment (i.e. at the end of treatment
course). Response was categorized as follows: No response, no
change or increase in the frequency of acute tonsillitis episodes;
Partial response, decrease in the frequency of acute tonsillitis
episodes by50%; and Total response, decrease in the frequency of
acute tonsillitis episodes by >50%. All responders to Broncho-
Vaxom were further followed beyond 3 months either at
subsequent follow-up visits or through a telephone interview
with the parents when follow-up visits were not available. Two
long-term outcomes were evaluated: remaining with a recurrent
infection rate of less than 3 times per year thus not requiring
tonsillectomy, or having a recurrence rate of 3 or more times per
year thus necessitating tonsillectomy.
2.1. Broncho-Vaxom
Each Broncho-Vaxom capsule contains 3.5 mg of lyophilized
bacterial lysates of Haemophilus inﬂuenzae, Diplococcus pneumo-
niae, Klebsiella pneumoniae and ozaenae, Staphylococcus aureus,
Streptococcus pyogenes and viridans,Neisseria catarrhalis. ExcipientsTable 1
Predictors for choice of initial treatment modality after study inclusion.
Parameter Broncho-Vaxom n=
Age in years, median (IQR) 4.0 (3.0–6.0)
Age <5 years, n/N (%) 73/131 (55.7)
Age 5 years, n/N (%) 58/131 (44.3)
Male, n/N (%) 85/131 (64.9)
Highly recurrent acute tonsillitis, n/N (%) 96/123 (78.0)
Positive ASO titer, n/N (%) 30/83 (36.1)
Elevated ESR level, n/N (%) 40/80 (50.0)
Elevated CRP level, n/N (%) 20/83 (24.1)
Elevated WBC count, n/N (%) 9/73 (12.3)
Anemia, n/N (%) 32/87 (36.8)
Abnormal urinalysis, n/N (%) 1/76 (1.3)
Positive throat culture, n/N (%) 10/33 (30.3)
URTI, upper respiratory tract infections; ASO, antistrepolysin O; ESR, erythrocyte sedimen
Laboratory deﬁnitions: positive ASO titer: 200 IU/ml; elevated ESR level: >20mm/h fo
>11,000/cumm; Anemia: hemoglobin level <12.0 g/dl; Abnormal urinalysis: any abnoinclude modiﬁed corn starch, magnesium silicate, magnesium
stearate, propyl gallate (E 310), sodium glutamate, mannitol,
gelatine, indigotine, titanium dioxide. The typical treatment
dosage is one capsule daily for 10 consecutive days per month
for a total of 3 months. The capsule is opened and the content is
dissolved in liquid (water, juice, or milk) and is given in the
morning on an empty stomach. If the child is old enough to
swallow the capsule then he/she will take it with a sip of water,
milk, or juice also in the morning on an empty stomach.
Concomitant antibiotic prophylaxis was undertaken for some
patients during the ﬁrst month of administration of Broncho-
Vaxom in an attempt to temporary suppress recurrence of
tonsillitis before getting the second (booster) course of Broncho-
Vaxom. In such cases, penicillin was used in a suspension form
(400 IU/5 ml) with an oral dose of 2.5 ml twice daily for children
younger than 5 years of age and 5 ml twice daily for those 5 years
and older.
2.2. Statistical analysis
Descriptive statistics are presented as medians (interquartile
range [IQR]) or percentages. Bivariate correlationswere done using
theMann–Whitney U test for continuous variables and the Fisher’s
exact test for categorical variables. Multivariate logistic regression
analysis was used to retrieve the adjusted odds ratios (OR) and 95%
conﬁdence intervals (CI) for study variables of interest, with
response to therapy being the dependent variable. All p-values are
two-sided with the level of signiﬁcance set at 0.05.
3. Results
A total of 177 patients presentedwith recurrent acute tonsillitis
during the study period. The median age was 4.5 years (IQR: 3.0–
6.3 years; min: 1 year; max: 15 years) including 113 (63.8%) boys
and 64 (36.2%) girls. The initial treatment modality was Broncho-
Vaxom in 131 (74%) patients while 38 (23.2%) had tonsillectomy
within a median of 1 month from presentation (IQR: 1.0–2.5
months; min: 1 month; max: 15 months). One month of
prophylactic antibiotics were concomitantly used in 80.5% of
patients receiving Broncho-Vaxom. Patients receiving Broncho-
Vaxom as the initial treatment modality had a similar age and sex
distribution compared with those who underwent tonsillectomy
(Table 1). Moreover, both groups of patients had a similar
proportion of patients with abnormal laboratory studies, in most
preformed tests (Table 1). However, the tonsillectomy group had a
higher proportion of patients with highly recurrent acute tonsillitis
(p = 0.017), a positive ASO titer (p = 0.028), or a positive throat
culture (p = 0.051) (Table 1).131 Tonsillectomy n=38 p-value
5.0 (3.9–7.0) 0.174
17/38 (44.7) 0.232
21/38 (55.3) 0.232
21/38 (55.3) 0.341
30/31 (96.8) 0.017
7/9 (77.8) 0.028
5/7 (71.4) 0.436
1/5 (20.0) 1.000
3/14 (21.4) 0.400
4/14 (28.6) 0.765
0/7 (0.0) 1.000
4/5 (80.0) 0.052
tation rate; CRP, C-reactive protein;WBC, white blood cell; IQR, interquartile range.
r females and >15mm/h for males; elevated CRP level: >2.5mg/l; elevated WBC:
rmality on visual exam, dipstick test, or microscopic exam.
Table 2
Predictors of response to Broncho-Vaxom therapy.
Parameter No response n=32 Response
All patients n=99 Partial response n=32 Total response n=67
Age in years, median (IQR) 4 (3–6) 4 (3–6) 4 (3–5) 5 (4–7)
Age <5 years, n/N (%) 18/32 (56.2) 55/99 (55.6) 23/32 (71.9) 32/67 (47.8)
Age 5 years, n/N (%) 14/32 (43.8) 44/99 (44.4) 9/32 (28.1) 35/67 (52.2)
Male, n/N (%) 22/32 (68.8) 63/99 (63.6) 22/32 (31.2) 41/67 (38.8)
Highly recurrent acute tonsillitis, n/N (%) 24/30 (80.0) 72/93 (77.4) 22/29 (75.9) 50/64 (78.1)
Positive ASO titer, n/N (%) 7/23 (30.4) 23/60 (38.3) 6/18 (33.3) 17/42 (40.5)
Elevated ESR level, n/N (%) 14/21 (66.7) 26/59 (44.1) 13/18 (72.2) 13/41 (31.7)*,yy
Elevated CRP level, n/N (%) 6/21 (28.6) 14/62 (22.6) 9/19 (47.7) 5/43 (11.6)yy
Elevated WBC count, n/N (%) 4/20 (20.0) 5/53 (9.4) 4/16 (25.0) 1/37 (2.7)*,y
Anemia, n/N (%) 5/23 (21.7) 27/64 (42.2) 10/22 (45.5) 17/42 (40.5)
Abnormal urinalysis, n/N (%) 1/19 (5.3) 0/57 (0.0) 0/18 (0.0) 0/39 (0.0)
Positive throat culture, n/N (%) 3/10 (30.0) 7/23 (30.4) 3/9 (33.3) 4/14 (28.6)
Concomitant antibiotics, n/N (%) 25/28 (89.3) 58/75 (77.3) 21/26 (80.8) 37/49 (75.5)
URTI, upper respiratory tract infections; ASO, antistrepolysin O; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein;WBC, white blood cell; IQR, interquartile range.
Laboratory deﬁnitions: positive ASO titer: 200 IU/ml; elevated ESR level: >20mm/h for females and >15mm/h for males; elevated CRP level: >2.5mg/l; elevated WBC:
>11,000/cu mm; anemia: hemoglobin level <12.0 g/dl; abnormal urinalysis: any abnormality on visual exam, dipstick test, or microscopic exam.
* p<0.05 compared with no response group.
y p<0.05.
yy p<0.01 compared with partial response group.
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Threemonths following Broncho-Vaxom administration, a total
of 99 (75.6%) patients showed response to therapy: 67 (51.2%)
patients showed total response while 32 (24.4%) showed partial
response. The remaining 32 (24.4%) patients showed no response.
Comparisons of study variables between the three response groups
are outlined in Table 2. Patients who showed total response were
less likely to have abnormal ESR compared with the partial
response (p = 0.005) and no response (p = 0.014) groups. Moreover,
they were less likely to have abnormal CRP levels compared with
the partial response group (p = 0.006). Patients who showed total
response were also less likely to have abnormal WBC count
compared with the partial response (p = 0.025) and no response
(p = 0.047) groups. On multivariate logistic regression analysis
including WBC count, ESR, and CRP levels, a normal ESR level was
the only predictor of total compared with no response (OR: 3.53,
95% CI: 1.03–12.07); while both normal ESR (OR: 7.15, 95% CI:
1.18–43.39) and normal CRP (OR: 12.66, 95% CI: 1.43–111.86)
levels were independent predictors of total over partial response.
3.2. Long-term follow-up in responders
Patients showing total response were further followed-up for a
median of 9 months (IQR: 3–27 months; min: 0 months; max: 45
months) and none required subsequent tonsillectomy. Patients
showing partial response were further followed-up for a median of
9 months (IQR: 3–12 months; min: 0 months; max: 45 months)
and 11 (34.4%) required subsequent tonsillectomy. The median
time to the need for tonsillectomy in those patients was 9 months
(range, 1–12 months).
4. Discussion
In this study, we demonstrated that a considerable proportion
of children treated with Broncho-Vaxom for recurrent acute
tonsillitis show a decrease in the frequency of episodes in the short
term, and very few patients eventually required tonsillectomy on
long-term follow up. Comparison between the results of our work
and those from previous studies remains challenging, as different
criteria are applied to deﬁne recurrent disease or response to
therapy, and most available studies included a cohort of patients
with varying upper respiratory tract infections. Nonetheless, ourﬁndings surely echo results from such clinical trials showing a
relative risk reduction in the frequency of upper respiratory tract
infections with Broncho-Vaxom therapy compared with placebo
[6,9–13]. The beneﬁt of Broncho-Vaxom in the primary prevention
of upper respiratory tract infections has also been demonstrated
[14]. It was also demonstrated that for children reporting at least
three upper respiratory tract infections during the previous winter
season, a 3-month preventive treatment with Broncho-Vaxom
provides substantial economic beneﬁts both for the insurers and
for society in general [15].
Defects in the immune systems are well known to be linked
with frequent respiratory tract infections. It has been shown that
57% of children with recurrent respiratory tract infections were
deﬁcient in one of the immunoglobulin (Ig) G subclasses and that
17% were IgA deﬁcient [16]. This correlation between recurrent
respiratory tract infections and immunological deﬁciencies
represents the rationale for a nonspeciﬁc immunostimulating
treatment for children suffering from recurrent infections. It may
also justify how a bacterial immunostimulant might prevent viral
infections, the most common cause of upper respiratory tract
infections in children. In support of this, our study found no
association between a positive ASO titer, a positive throat culture,
or use of concomitant 1 month prophylactic antibiotics and
response to Broncho-Vaxom therapy.
Previous studies have identiﬁed that the most notable
predictors of response to Broncho-Vaxom therapy are age (younger
children) and the frequency of previous acute episodes [6]. Our
study did not observe such an association, whichmay be attributed
to the small sample size upon stratiﬁcation. However, we found a
strong association between response to therapy and ESR or CRP
levels at baseline, where children having normal levels were more
likely to achieve response to therapy. The utilities of ESR and CRP in
the diagnosis and follow-up of infections that occur in children
have been the subject of many studies. Emphasis has mostly been
placed on differentiating between acute bacterial and acute viral
infections of the respiratory tract because of the obvious
differences in patient management. CRP levels are generally
higher in patients with streptococcal tonsillitis compared to
patients with tonsillitis without group A streptococcus isolated
from a throat swab; while ESR cannot reliably distinguish the
microbial etiology [17]. In light of the lack of association between
conﬁrmed bacterial etiology and response to Broncho-Vaxom
therapy in our study, the predictive ability of CRP or ESR levels
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and further studies are needed to explain the observed ﬁnding.
However, irrespective of the underlyingmechanism,measurement
of bothmarkers may prove useful to outline patients that are more
likely to show beneﬁt; a strategy that could be of importance in
developing countries with limited resources.
We tried to identify factors that may have inﬂuenced the
physician’s choice of performing a tonsillectomy rather than using
a bacterial immunostimulant upon the child’s initial presentation
with a history of recurrent acute tonsillitis. It was noted that a
suspicion of a bacterial etiology was the main factor favoring the
choice of tonsillectomy. However, our study herein conﬁrms that
the etiology of tonsillitis does not affect response to Broncho-
Vaxom. In all cases, we recommend that an individualized
approach with a careful risk-beneﬁt assessment should be applied.
The main limitation is that we conducted an observational
study for a therapeutic intervention, which means that confound-
ing by indication, patient characteristics, or use of antibiotics
cannot be fully ruled. Such factors can only be addressed in a
randomized controlled trial recruiting patients without any
concomitant antibiotic use. Nonetheless, in our study patients
received antibiotics (in a prophylactic dose) only during the ﬁrst
month of treatment with Broncho-Vaxom, to temporary suppress
the recurrence of infections. Such short duration of prophylaxis is
unlikely to affect the short (3 months) or long-term effects on
response.
In conclusion, our study highlights the beneﬁt of bacterial
immunostimulant therapy with Broncho-Vaxom for the manage-
ment of recurrent acute tonsillitis in childhood. Further random-
ized studies are needed to better identify which patients show the
most favorable response, ideally using patient-related factors or
laboratorymarkers that are commonly available at a relatively low
cost.
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